255 related articles for article (PubMed ID: 27530055)
1. The Role of Conditioning in Hematopoietic Stem-Cell Gene Therapy.
Bernardo ME; Aiuti A
Hum Gene Ther; 2016 Oct; 27(10):741-748. PubMed ID: 27530055
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Mobilization-based engraftment of haematopoietic stem cells: a new perspective for chemotherapy-free gene therapy and transplantation.
Canarutto D; Omer Javed A; Pedrazzani G; Ferrari S; Naldini L
Br Med Bull; 2023 Sep; 147(1):108-120. PubMed ID: 37460391
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
[TBL] [Abstract][Full Text] [Related]
5. Factors affecting engraftment of allogeneic hematopoietic stem cells after reduced-intensity conditioning.
Walshe J; Bishop MR
Cytotherapy; 2004; 6(6):589-2. PubMed ID: 15773022
[TBL] [Abstract][Full Text] [Related]
6. Non-genotoxic Restoration of the Hematolymphoid System in Fanconi Anemia.
Chan YY; Ho PY; Swartzrock L; Rayburn M; Nofal R; Thongthip S; Weinberg KI; Czechowicz A
Transplant Cell Ther; 2023 Mar; 29(3):164.e1-164.e9. PubMed ID: 35995393
[TBL] [Abstract][Full Text] [Related]
7. The transplantation of hematopoietic stem cells after non-myeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases.
Maris M; Storb R
Immunol Res; 2003; 28(1):13-24. PubMed ID: 12947221
[TBL] [Abstract][Full Text] [Related]
8. Viral interleukin-10-engineered autologous hematopoietic stem cell therapy: a novel gene therapy approach to prevent graft rejection.
Salgar SK; Yang D; Ruiz P; Miller J; Tzakis AG
Hum Gene Ther; 2004 Feb; 15(2):131-44. PubMed ID: 14975186
[TBL] [Abstract][Full Text] [Related]
9. Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies.
Chiesa R; Veys P
Expert Rev Clin Immunol; 2012 Mar; 8(3):255-66; quiz 267. PubMed ID: 22390490
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant.
Yeung J; Liao A; Shaw M; Silva S; Vetharoy W; Rico DL; Kirby I; Zammarchi F; Havenith K; de Haan L; van Berkel PH; Sebire N; Ogunbiyi OK; Booth C; Gaspar HB; Thrasher AJ; Chester KA; Amrolia PJ
Mol Ther; 2024 Jun; 32(6):1672-1686. PubMed ID: 38549377
[TBL] [Abstract][Full Text] [Related]
11. Successful Allogeneic Hematopoietic Stem Cell Transplantation in XIAP Deficiency Using Reduced-Intensity Conditioning.
Chellapandian D; Krueger J; Schechter T; Gassas A; Weitzman S; Naqvi A; Ali M
Pediatr Blood Cancer; 2016 Feb; 63(2):355-7. PubMed ID: 26398727
[TBL] [Abstract][Full Text] [Related]
12. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
13. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
Cieri N; Greco R; Crucitti L; Morelli M; Giglio F; Levati G; Assanelli A; Carrabba MG; Bellio L; Milani R; Lorentino F; Stanghellini MT; De Freitas T; Marktel S; Bernardi M; Corti C; Vago L; Bonini C; Ciceri F; Peccatori J
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1506-14. PubMed ID: 26001696
[TBL] [Abstract][Full Text] [Related]
14. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow.
Kramer BA; Lemckert FA; Alexander IE; Gunning PW; McCowage GB
J Gene Med; 2006 Sep; 8(9):1071-85. PubMed ID: 16927363
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic haemopoietic stem cell transplantation using non-myeloablative conditioning--a local experience.
Leong CF; Cheong SK; Fadilah SA; Ainoon O; Hamidah NH
Med J Malaysia; 2003 Jun; 58(2):229-35. PubMed ID: 14569743
[TBL] [Abstract][Full Text] [Related]
17. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011-2012: A comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT).
Aljurf M; Nassar A; Hamidieh AA; Elhaddad A; Hamladji RM; Bazarbachi A; Ibrahim A; Ben Othman T; Abdel-Rahman F; Alseraihy A; Fahmy O; Hussein AA; Alabdulaaly A; Adil S; Alkindi SS; Bayoumy M; Dennison D; Bekadja MA; Redhouane AN; Rasheed W; AlSagheir A; Alsudairy R; Ladeb S; Benchekroun S; Ramzi M; Ahmed P; ElSolh H; Ahmed SO; Hussain F; Ghavamzadeh A
Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):167-75. PubMed ID: 26452331
[TBL] [Abstract][Full Text] [Related]
20. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study.
Straathof KC; Rao K; Eyrich M; Hale G; Bird P; Berrie E; Brown L; Adams S; Schlegel PG; Goulden N; Gaspar HB; Gennery AR; Landais P; Davies EG; Brenner MK; Veys PA; Amrolia PJ
Lancet; 2009 Sep; 374(9693):912-20. PubMed ID: 19729196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
